Key facts
- European Commission approves Amgen's Imdyetra for extensive-stage small cell lung cancer.
- Approval is based on Phase 3 DeLLphi-304 trial results.
- Imdyetra demonstrated a 40% reduction in the risk of death compared to chemotherapy.
- The drug offers a novel treatment option for patients with progressive extensive-stage small cell lung cancer.
The European Commission's approval of Amgen's Imdyetra marks a significant development in the treatment of extensive-stage small cell lung cancer (SCLC). SCLC is an aggressive form of lung cancer with limited treatment options once it progresses beyond the initial stage. This approval provides a new therapeutic avenue for patients who have exhausted standard chemotherapy regimens.